Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1993 May;52(5):360–364. doi: 10.1136/ard.52.5.360

Hydroxychloroquine treatment for primary Sjögren's syndrome: a two year double blind crossover trial.

A A Kruize 1, R J Hené 1, C G Kallenberg 1, O P van Bijsterveld 1, A van der Heide 1, L Kater 1, J W Bijlsma 1
PMCID: PMC1005050  PMID: 8323383

Abstract

OBJECTIVES--In 1985 and 1988 a positive effect of treatment of primary Sjögren's syndrome with hydroxychloroquine was reported in two small open studies. To investigate further the clinical and laboratory effects of hydroxychloroquine in primary Sjögren's syndrome a two year study was performed. METHODS--The design of the study included a prospective, placebo controlled, two year double blind crossover trial in 19 patients. RESULTS--A significant decrease in IgG and IgM and a tendency for a decrease in the erythrocyte sedimentation rate (ESR) during treatment with hydroxychloroquine compared with treatment with placebo were found. No beneficial clinical effect of the use of hydroxychloroquine as expressed in preference for treatment with hydroxychloroquine or placebo with regard to symptoms and signs of primary Sjögren's syndrome could be shown, however, nor any relevant change in tear gland activity and sequelae of peripheral tear function deficiency, nor salivary gland scintigraphy. CONCLUSIONS--The use of hydroxychloroquine at a dose of 400 mg daily taken over a 12 month period does not have a worthwhile clinical benefit in patients with primary Sjögren's syndrome despite an improvement of hyperglobulinaemia and slight changes in the ESR and IgM.

Full text

PDF
360

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. FREEDMAN A., STEINBERG V. L. Chloroquine in rheumatoid arthritis; a double blindfold trial of treatment for one year. Ann Rheum Dis. 1960 Sep;19:243–250. doi: 10.1136/ard.19.3.243. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Fox R. I., Chan E., Benton L., Fong S., Friedlaender M., Howell F. V. Treatment of primary Sjögren's syndrome with hydroxychloroquine. Am J Med. 1988 Oct 14;85(4A):62–67. doi: 10.1016/0002-9343(88)90365-8. [DOI] [PubMed] [Google Scholar]
  3. Fox R. I., Robinson C. A., Curd J. G., Kozin F., Howell F. V. Sjögren's syndrome. Proposed criteria for classification. Arthritis Rheum. 1986 May;29(5):577–585. doi: 10.1002/art.1780290501. [DOI] [PubMed] [Google Scholar]
  4. Hené R. J., Kruize A. A., Bijlsma J. W., Kater L. Morbus Sjögren, more than a dry syndrome. Neth J Med. 1992 Apr;40(3-4):108–112. [PubMed] [Google Scholar]
  5. Hills M., Armitage P. The two-period cross-over clinical trial. Br J Clin Pharmacol. 1979 Jul;8(1):7–20. doi: 10.1111/j.1365-2125.1979.tb05903.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Kassan S. S., Thomas T. L., Moutsopoulos H. M., Hoover R., Kimberly R. P., Budman D. R., Costa J., Decker J. L., Chused T. M. Increased risk of lymphoma in sicca syndrome. Ann Intern Med. 1978 Dec;89(6):888–892. doi: 10.7326/0003-4819-89-6-888. [DOI] [PubMed] [Google Scholar]
  7. Klaassen-Broekema N., Mackor A. J., van Bijsterveld O. P. The diagnostic power of the tests for tear gland related keratoconjunctivitis sicca. Neth J Med. 1992 Apr;40(3-4):113–116. [PubMed] [Google Scholar]
  8. Klinefelter H. F., Achurra A. Effect of gold salts and antimalarials on the rheumatoid factor in rheumatoid arthritis. Scand J Rheumatol. 1973;2(4):177–182. doi: 10.3109/03009747309097086. [DOI] [PubMed] [Google Scholar]
  9. Kruize A. A., Hené R. J., Oey P. L., Kater L., Bijlsma J. W. Neuro-musculo-skeletal manifestations in primary Sjögren's syndrome. Neth J Med. 1992 Apr;40(3-4):135–139. [PubMed] [Google Scholar]
  10. Lakhanpal S., Duffy J., Griffing W. L., Conn D. L., Luthra H. S. Sjögren's syndrome: treatment with D-penicillamine and hydroxychloroquine. J Rheumatol. 1985 Oct;12(5):1028–1029. [PubMed] [Google Scholar]
  11. Mishkin F. S. Radionuclide salivary gland imaging. Semin Nucl Med. 1981 Oct;11(4):258–265. doi: 10.1016/s0001-2998(81)80023-2. [DOI] [PubMed] [Google Scholar]
  12. Runge L. A. Risk/benefit analysis of hydroxychloroquine sulfate treatment in rheumatoid arthritis. Am J Med. 1983 Jul 18;75(1A):52–56. doi: 10.1016/0002-9343(83)91271-8. [DOI] [PubMed] [Google Scholar]
  13. van Bijsterveld O. P. Diagnostic tests in the Sicca syndrome. Arch Ophthalmol. 1969 Jul;82(1):10–14. doi: 10.1001/archopht.1969.00990020012003. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES